Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cyclosporin A Restasis

PreclinicalSmall molecule

MMedical University of South Carolina

Cyclosporin A Restasis is one of 2 small molecule programs targeting Dry Eye Symptoms. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry Eye SymptomsCompleted

Dry Eye SymptomsPreclinical

Completed

Competition

Competitive Landscape

2 competitors in Dry Eye Symptoms

#DrugCompanyPhaseTrials

Cyclosporin A Restasis

MMedical University of South Carolina

Blink Tears

MMedical University of South Carolina

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dry Eye Symptoms1 trial

Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms

Completed·MMedical University of South Carolina·N/A·NCT00565669·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cyclosporin A Restasis. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclosporin A Restasis compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclosporin A Restasis. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of South Carolina company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of South Carolina

Related News